A Resource for Healthcare and Social Services Professionals
May 17, 2022
5:30 pm–6:00 pm ET
This 30 minute session, titled “The Pharmacist’s Introduction to Injectable Buprenorphine,” will provide an overview of the medication. The role of the pharmacist/pharmacy technician, initiation strategies, and a review of the medication will be discussed.
Via Zoom Webinar
This 30 minute session, titled “The Pharmacist’s Introduction to Injectable Buprenorphine,” will provide an overview of the medication. The role of the pharmacist/pharmacy technician, initiation strategies, and a review of the medication will be discussed. By attending this 30 minute session, pharmacists and pharmacy technicians will be better prepared to work with patients who need these monthly injections.
This activity is intended for pharmacists and pharmacy technicians working as part of the healthcare team to treat patients for substance use disorder.
PharmD, BCPP
Neuroscience Medical Science Liaison at Otsuka Pharmaceutical Companies
Dr. Alyssa Peckham is a board certified psychiatric clinical pharmacist specializing in various psychiatric and substance use disorders. She received her PharmD from the University of Rhode Island and completed two years of postgraduate residency training in psychiatry at the Veterans Affairs Hospital in Connecticut. Prior to her current role, she practiced as an advanced practice pharmacist in the Bridge Clinic at Massachusetts General Hospital in Boston which is a low threshold, harm reduction clinic for people with substance use disorders. Her research is focused on the use and misuse of prescriptions and other substances, with a focus on pharmacotherapy and harm reduction
Pharmacists Learning Objectives: At the completion of this activity, the participant will be able to:
Explain buprenorphine injection pharmacology, role in the treatment of OUD, safety, efficacy, and outcomes
Compare and contrast different injectable buprenorphine's initiation strategies.
Define the current role of the pharmacist regarding use of injectable buprenorphine and potential role progression in the future
Pharmacy Technicians Learning Objectives: At the completion of this activity, the participant will be able to:
Explain injectable buprenorphine's pharmacology, role in the treatment of OUD, safety, efficacy, and outcomes
Define the current role of the pharmacy technicians regarding use of injectable buprenorphine's and potential role progression in the future
Boston Medical Center Office-Based Addiction Treatment Training and Technical Assistance +, The Association for Multidisciplinary Education and Research in Substance Use and Addiction
Hosted on: Zoom Webinar
Topic Designator: Drug Therapy
Activity Type: Knowledge-based
Pharmacist | UAN 0026-9999-22-096-L01-P
Pharmacy Technician | UAN 0026-9999-22-096-L01-T
Accreditation
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MCPHS designates this educational activity for a total of 0.5 contact hours (0.05 CEUs).
Requirements for Credit
Attendance will be verified. Partial credit will not be awarded. Credit will not be issued to participants who join the meeting more than 7 minutes after the start of the meeting or to those who depart early. In order to receive credit you will need to complete the session evaluation within two weeks of attending the event.
Statement of Disclosure
Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of MCPHS that the speakers and planning committee members disclose all financial relationships with ineligible companies, and that relevant conflicts of interest are mitigated. Speakers will disclose any unlabeled/unapproved use of drugs or devices during their presentation.
Alyssa M. Peckham is employed by Otsuka Pharmaceutical Companies as a Neuroscience Medical Science Liaison.
Jeffery Bratberg holds no relevant financial relationship with ineligible companies.
OBAT TTA planning committee members have no relevant financial relationships with ineligible companies to disclose.
All MCPHS CE staff members have no relevant financial relationships with ineligible companies to disclose.
Grayken Center for Addiction TTA is a program of Boston Medical Center (BMC), a 514-bed academic medical center located in Boston's historic South End and the largest safety-net hospital in New England.
The content on this site and the content presented by Grayken Center for Addiction TTA is intended solely to inform and educate healthcare and social service professionals, and shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional. The hospital, the program, and the contributors are not acting as health care providers or professional consultants on behalf of any specific patient and disclaim establishing a provider-patient relationship with any specific patient.